Progress in the emergency management of hereditary Angioedema: Focus on new treatment options in the United States

Postgraduate Medicine

Volumn 124, Issue 3, 2012, Pages 91-100

  Bernstein, Jonathan A ^a   Moellman, Joseph J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Acute hereditary angioedema attack; Ecallantide; Hereditary angioedema; Icatibant; Nonal lergic; Nonpitting edema; Nonpruritic; Plasma derived C1 esterase inhibitor; Recombinant human C1 esterase inhibitor

Indexed keywords

AMINOCAPROIC ACID; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; ECALLANTIDE; FRESH FROZEN PLASMA; ICATIBANT; PLACEBO; RECOMBINANT PROTEIN; TRANEXAMIC ACID; BRADYKININ; COMPLEMENT INHIBITOR; DRUG DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE;

ALGORITHM; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; DIAGNOSTIC PROCEDURE; DISEASE TRANSMISSION; DIZZINESS; DRUG APPROVAL; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; EMERGENCY CARE; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEALTH CARE NEED; HUMAN; HYPERTENSION; INJECTION SITE REACTION; MENSTRUAL IRREGULARITY; MORTALITY; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINUSITIS; THROMBOSIS; TOXIC HEPATITIS; TREATMENT OUTCOME; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VIRILIZATION; WEIGHT GAIN; EMERGENCY TREATMENT; REVIEW;

ANGIOEDEMAS, HEREDITARY; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRADYKININ; COMPLEMENT C1 INHIBITOR PROTEIN; COMPLEMENT INACTIVATING AGENTS; EMERGENCY TREATMENT; HUMANS; PEPTIDES; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 84867879151     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.05.2552     Document Type: Article

References (52)

1. Davis AE III. New treatments addressing the pathophysiology of hereditary angioedema. Clin Mol Allergy. 2008;6:2.
2. Papadopoulou-Alataki E. Upper airway considerations in hereditary angioedema. Curr Opin Allergy Clin Immunol. 2010;10(1):20-25.
3. Zuraw BL. Hereditary angioedema. N Engl J Med. 2008;359(10): 1027-1036.
4. Bernstein JA. Hereditary angioedema: a current state-of-the-art review, VIII: current status of emerging therapies. Ann Allergy Asthma Immunol. 2008;100(suppl 2):S41-S46.
5. Agostoni A, Aygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress-proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114(3 suppl):S51-S131.
6. C1 Inhibitor Gene Mutation Database. National Medical Center, Laboratory of Molecular Biology. http://hae.enzim.hu. Accessed April 24, 2012.
7. Prada AE, Zahedi K, Davis AE 3rd. Regulation of C1 inhibitor synthesis. Immunobiology. 1998;199(2):377-388.
8. Binkley KE, Davis A 3rd. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol. 2000;106(3):546-550.
9. Bork K, Gul D, Dewald G. Hereditary angio-oedema with normal C1 inhibitor in a family with affected women and men. Br J Dermatol. 2006;154(3):542-545.
10. Bork K, Meng G, Stauback P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs and course. Am J Med. 2006;119(3):267-274.
11. Farkas H, Jakab L, Temesszentandrasi G, et al. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol. 2007;120(4):941-947.
12. Kemp JG, Craig TJ. Variability of prodromal signs and symptoms associated with hereditary angioedema attacks: a literature review. Allergy Asthma Proc. 2009;30(5):493-499.
13. Frank MM. Hereditary angioedema: the clinical syndrome and its management in the United States. Immunol Allergy Clin North Am. 2006;26(4):653-668.
14. Bork K. Hereditary angioedema with normal C1 inhibitor activity including hereditary angioedema with coagulation factor XII gene mutations. Immunol Allergy Clin North Am. 2006;26(4):709-724.
15. Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med. 1976;84(5):580-593.
16. Weis M. Clinical review of hereditary angioedema: diagnosis and management. Postgrad Med. 2009;121(6):113-121.
17. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol. 2005;139(3):379-394.
18. Bork K, Siedlecki K, Bosch S, et al. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc. 2000;75(4):349-354.
19. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;124(4):801-808.
20. Craig TJ. Appraisal of danazol prophylaxis for hereditary angioedema. Allergy Asthma Proc. 2008;29(3):225-231.
21. Levi M, Choi G, Picavet C, Hack CE. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1 -inhibitor deficiency. J Allergy Clin Immunol. 2006;117(4):904-908.
22. Cinryze [package insert]. Exton, PA: ViroPharma; 2008.
23. Sondhi D, Lippmann M, Murali G. Airway compromise due to angiotensin-converting enzyme inhibitor-induced angioedema: clinical experience at a large community teaching hospital. Chest. 2004;126(2):400-404.
24. Vleeming W, van Amsterdam JG, Stricker BH, de Wildt DJ. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf. 1998;18(3):171-188.
25. Bas M, Hoffmann T, Kojda G. Evaluation and management of angioedema of the head and neck. Curr Opin Otolaryngol Head Neck Surg. 2006;14(3):170-175.
26. Korniyenko A, Alviar CL, Cordova JP, Messerli FH. Visceral angioedema due to angiotensin-converting enzyme inhibitor therapy. Cleve Clin J Med. 2011;78(5):297-304.
27. Winters M. Clinical practice guideline: Initial evaluation and management of patients presenting with acute urticaria or angioedema (7/10/06). Milwaukee, WI: American Academy of Emergency Medicine; Jul 10, 2006. http://www.aaem.org/positionstatements/clinical_practice_guide-lines.php. Accessed February 23, 2010.
28. Bowen T, Cicardi M, Bork K, et al. Hereditary angioedema: a current state-of-the-art review, VII: Canadian Hungarian 2007 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. Ann Allergy Asthma Immunol. 2008;100(suppl 2):S30-S40.
29. Pekdemir M, Ersel M, Aksay E, et al. Effective treatment of hereditary angioedema with fresh frozen plasma in an emergency department. J Emerg Med. 2007;33(2):137-139.
30. Prematta M, Gibbs JG, Pratt EL, et al. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol. 2007;98(4):383-388.
31. Frank MM, Jiang H. New therapies for hereditary angioedema: disease outlook changes dramatically. J Allergy Clin Immunol. 2008;121(1):272-280.
32. Prematta MJ, Prematta T, Craig TJ. Treatment of hereditary angioedema with plasma-derived C1 inhibitor. Ther Clin Risk Manage. 2008;4(5):975-982.
33. Berinert® [C1 Esterase Inhibitor (Human)] [package insert]. Marburg, Germany: CSL Behring GmbH; December, 2011.
34. Craig TJ, Bewtra AK, Bahna SL, et al. C1 esterase inhibitor concentrate in 1085 hereditary angioedema attacks-final results of the I.M.P.A.C.T2 study. Allergy 2011;66(12):1604-1611.
35. Bork K, Meng G, Stauback P, Hardt J. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion. 2005;45(11):1774-1784.
36. Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med. 2001;161(5):714-718.
37. De Serres J, Gröner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert) in hereditary angioedema: a review. Transfus Apher Sci. 2003;29(3):247-254.
38. Kalbitor [package insert]. Cambridge, MA: Dyax Corp; 2009.
39. Levy R, McNeil D, Li H, et al. Results of a 2-stage, phase 3 pivotal trial EDEMA3: a study of subcutaneous DX-88 (ecallantide), a plasma kallikrein inhibitor, in patients with hereditary angioedema (HAE). J Allergy Clin Immunol. 2008;121(2 suppl 1):S231.
40. Lunn M, Banta E. Ecallantide for the treatment of hereditary angioedema in adults. Clin Med Insights Cardiol. 2011;5:49-54.
41. Levy R, Lumry WR, McNeil DL, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104(6):523-529.
42. Firazyr [package insert]. Lexington, MA: Shire Orphan Therapeutics, Inc; 2011.
43. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363(6):532-541.
44. Lumry WR, Li HH, Levy RJ, et al. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment fo acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol. 2011;107(6):529-537.
45. Longhurst HJ. Management of acute attacks of hereditary angioedema: potential role of icatibant. Vasc Health Risk Manag. 2010;6: 795-802.
46. Choi G, Soeters MR, Farkas H, et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion. 2007;47(6):1028-1032.
47. Nuijens J, Verdonk R, Giannetti B, et al. Clinical studies of recombinant human c1 inhibitor (rhC1INH) in patients with acute attacks of hereditary angioedema. J Allergy Clin Immunol. 2008;121(3):797.
48. Sardana N, Craig TJ. Recent advances in management and treatment of hereditary angioedema. Pediatrics. 2011;128(6):1173-1180.
49. Varga L, Farkas H. rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency. Expert Rev Clin Immunol. 2011;7(2):143-153.
50. Kreuz W, Rusicke E, Martinez-Saguer I, et al. Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Transfusion. 2012;52(1):100-107.
51. Tourangeau LM, Castaldo AJ, Davis DK, Koziol J, Christiansen SC, Zuraw BL. Safety and efficacy of physician-supervised self-managed C1 inhibitor replacement therapy. Int Arch Allergy Immunol. 2012;157(4):417-424.
52. Banerji A, Sheffer AL. The spectrum of chronic angioedema. Allergy Asthma Proc. 2009;30(1):11-16.